AhBeee personal page - To The Moon

AhBeee

AhBeee

No personal profile

25Follow

1Followers

0Topic

0Badge

01-21

$Tesla Motors(TSLA)$ go go go

2022-10-24

$Tesla Motors(TSLA)$go go go

2022-10-25

$DiDi Global Inc.(DIDIY)$fml worng time

2022-08-15

$DiDi Global Inc.(DIDIY)$omg

2022-08-13

$DiDi Global Inc.(DIDIY)$omg

2022-08-06

$Meta Platforms, Inc.(META)$pray

2022-08-03

[Like]

Pre-Bell｜U.S. Stock Index Futures Rise; PayPal Stock Surges 13%

2022-08-01

$Palantir Technologies Inc.(PLTR)$buy or not buy?

2022-07-27

[Like]

Alphabet Shares Jumped 4.57% as Search Ads Topping Wall Street Targets

2022-10-07

$Meta Platforms, Inc.(META)$omg hai...

2022-09-25

$Meta Platforms, Inc.(META)$pray hard

2022-08-15

$S&P 500(.SPX)$bull

2022-08-09

$Palantir Technologies Inc.(PLTR)$go go go

2022-08-03

[Like]

CVS Health Gains As All-Around Performance Drives Strong 2Q Beat

04-26

$Alphabet(GOOGL)$ go go go

2022-10-18

$Meta Platforms, Inc.(META)$to moon pls

2022-10-07

Ok

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

2022-09-24

$Amazon.com(AMZN)$zzz omg

2022-09-23

$AMC Entertainment(AMC)$zzz

2022-08-04

$Palantir Technologies Inc.(PLTR)$can buy?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4115099382320642,"uuid":"4115099382320642","gmtCreate":1653441557809,"gmtModify":1702472467943,"name":"AhBeee","pinyin":"ahbeee","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","hatId":"shopping-c3edc01e31206bedfff9b5eecea7bb42","hatName":"2023 New Year ","vip":1,"status":2,"fanSize":1,"headSize":25,"tweetSize":51,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.12","exceedPercentage":"60.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":9,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":299506467254432,"gmtCreate":1714141119772,"gmtModify":1714141125243,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> go go go","listText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> go go go","text":"$Alphabet(GOOGL)$ go go go","images":[{"img":"https://community-static.tradeup.com/news/40d83422b1fa384a85031ce6f750d06c","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/299506467254432","isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":265396300406912,"gmtCreate":1705818058033,"gmtModify":1705818062018,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go","text":"$Tesla Motors(TSLA)$ go go go","images":[{"img":"https://community-static.tradeup.com/news/66c6acbdf68373dd06c0fc027420b4bd","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/265396300406912","isVote":1,"tweetType":1,"viewCount":424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":251773211283744,"gmtCreate":1702511406071,"gmtModify":1702511409013,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a>&nbsp;[Cry]&nbsp;&nbsp;pls go up","listText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a>&nbsp;[Cry]&nbsp;&nbsp;pls go up","text":"$Sea Ltd(SE)$ [Cry] pls go up","images":[{"img":"https://community-static.tradeup.com/news/5c00c88309786171333e24acd7002513","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251773211283744","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":251609171800296,"gmtCreate":1702465378593,"gmtModify":1702472350993,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go... pls go back up","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go... pls go back up","text":"$Tesla Motors(TSLA)$ go go go... pls go back up","images":[{"img":"https://community-static.tradeup.com/news/bf483f42e48b94cca557293a81ca5c53","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251609171800296","isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":251608759115832,"gmtCreate":1702465131520,"gmtModify":1702472278049,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"The day will get better soon","listText":"The day will get better soon","text":"The day will get better soon","images":[{"img":"https://community-static.tradeup.com/news/cb763fe4996286a375c498cb759cae39","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251608759115832","isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":244572077273104,"gmtCreate":1700734000973,"gmtModify":1700734005268,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Coin... more coin... 1000 coin","listText":"Coin... more coin... 1000 coin","text":"Coin... more coin... 1000 coin","images":[{"img":"https://community-static.tradeup.com/news/8c1702ff35646e2ec06a155c1622e43f","width":"1080","height":"2280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/244572077273104","isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":244572326387904,"gmtCreate":1700733951921,"gmtModify":1700733956427,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Coin... more coin...","listText":"Coin... more coin...","text":"Coin... more coin...","images":[{"img":"https://community-static.tradeup.com/news/8c1702ff35646e2ec06a155c1622e43f","width":"1080","height":"2280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/244572326387904","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":234308419457256,"gmtCreate":1698240939286,"gmtModify":1698240944029,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Pray hard&nbsp; all green","listText":"Pray hard&nbsp; all green","text":"Pray hard all green","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/234308419457256","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183086871085072,"gmtCreate":1685720557529,"gmtModify":1685720561281,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SOFI\">$SoFi Technologies Inc.(SOFI)$ &nbsp;</a>?","listText":"<a href=\"https://ttm.financial/S/SOFI\">$SoFi Technologies Inc.(SOFI)$ &nbsp;</a>?","text":"$SoFi Technologies Inc.(SOFI)$ ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183086871085072","isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9988329721,"gmtCreate":1666670982363,"gmtModify":1676537787465,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>fml worng time","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>fml worng time","text":"$DiDi Global Inc.(DIDIY)$fml worng time","images":[{"img":"https://community-static.tradeup.com/news/e1ed96aa3b9dc2838c98488bdd0a880b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988329721","isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9981575285,"gmtCreate":1666575534948,"gmtModify":1676537769707,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>go go go","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>go go go","text":"$Tesla Motors(TSLA)$go go go","images":[{"img":"https://community-static.tradeup.com/news/5c13289c8a69826c36bddd56fc9f669a","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9981575285","isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9983718021,"gmtCreate":1666318181364,"gmtModify":1676537740252,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>fly to moon","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>fly to moon","text":"$Palantir Technologies Inc.(PLTR)$fly to moon","images":[{"img":"https://community-static.tradeup.com/news/31802e9e3ab887551f106f913083e6b8","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983718021","isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9983711688,"gmtCreate":1666318117045,"gmtModify":1676537740235,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a>bear","listText":"<a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a>bear","text":"$S&P 500(.SPX)$bear","images":[{"img":"https://community-static.tradeup.com/news/c4e8ee256f4769e10ce186879d9488e0","width":"1080","height":"1575"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983711688","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9983696795,"gmtCreate":1666225469117,"gmtModify":1676537724669,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NFLX\">$Netflix(NFLX)$</a>go go go","listText":"<a href=\"https://ttm.financial/S/NFLX\">$Netflix(NFLX)$</a>go go go","text":"$Netflix(NFLX)$go go go","images":[{"img":"https://community-static.tradeup.com/news/ed5b12c9de2517376aa9fb3450ead8f3","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983696795","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9989546911,"gmtCreate":1666052375333,"gmtModify":1676537697196,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>to moon pls","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>to moon pls","text":"$Meta Platforms, Inc.(META)$to moon pls","images":[{"img":"https://community-static.tradeup.com/news/e67a4cbbc235d8ae4a1aacda1bb6444b","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9989546911","isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9989548255,"gmtCreate":1666052337577,"gmtModify":1676537697188,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>go go go","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>go go go","text":"$Apple(AAPL)$go go go","images":[{"img":"https://community-static.tradeup.com/news/8964d6573d40c43afd80113bdf8d94b1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9989548255","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9917409354,"gmtCreate":1665551420078,"gmtModify":1676537626208,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>bbq","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>bbq","text":"$Apple(AAPL)$bbq","images":[{"img":"https://community-static.tradeup.com/news/e2cd216de004ad817a24ad9d2347605c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9917409354","isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9915729552,"gmtCreate":1665111708476,"gmtModify":1676537559613,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Gogo..","listText":"Gogo..","text":"Gogo..","images":[{"img":"https://community-static.tradeup.com/news/27a11932a1156e3a863200a335b2f56a","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915729552","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9915729962,"gmtCreate":1665111678156,"gmtModify":1676537559598,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>omg hai...","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>omg hai...","text":"$Meta Platforms, Inc.(META)$omg hai...","images":[{"img":"https://community-static.tradeup.com/news/4e0471fa9a70616976e358099f3707b3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9915729962","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9915720961,"gmtCreate":1665111550153,"gmtModify":1676537559572,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915720961","repostId":"2273828361","repostType":4,"repost":{"id":"2273828361","pubTimestamp":1665108107,"share":"https://www.laohu8.com/m/news/2273828361?lang=&edition=full","pubTime":"2022-10-07 10:01","market":"us","language":"en","title":"Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2273828361","media":"InvestorPlace","summary":"Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech ","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/11abc7bc1b026070774bd992fe8fb96d\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\"/></p><p>Source: Shutterstock</p><p>In October 2021, I made a big call on <b>Longeveron</b> (NASDAQ:<b>LGVN</b>) stock, a biotech firm working on a promising Alzheimer’s therapy.</p><p>Within six weeks, shares had risen over 11x… a stunning 1,000% return!</p><p>My secret?</p><p>I noticed that the biotech’s CFO was quietly buying shares in the company.</p><p>“With clinical results due within the next month, Longeveron’s executives are likely using their knowledge of the Aging Frailty study to predict a strong outcome in the Alzheimer’s trial.”</p><p>Just a month later, the company would announce some unexpectedly good news: The U.S. Food and Drug Administration (FDA) approved Longeveron’s Lomecel-B for use!</p><h2>The Secret to Finding 1,000% Winners</h2><p>It turns out that Longeveron’s management aren’t the only ones who are suspiciously good at timing their company’s stock.</p><p>A study by MIT researchers found that insider transactions in the U.S. would have turned $10,000 into $156,000 over their study period, compared to around $50,300 in the <b>S&amp;P 500</b>.</p><p>That’s because insiders often act on privileged information, both knowingly and unknowingly. If sales figures are doing well… or patients are responding well to clinical trials… they don’t need the “official” SEC filings to decide to buy.</p><p>Some call it a total scam.</p><p>And I get it. SEC rules around insider transactions are surprisingly lax; if a CEO sees a new product performing well or is on the cusp of making a massive deal, it’s often entirely legal to trade on that information. In 2018, <b>Tesla</b> (NASDAQ:<b>TSLA</b>) CEO Elon Musk bought $25 million of his company’s shares while details of a massive $2 billion capital raise were still under wraps.</p><p>TSLA shares would rise 206% within a year.</p><p>But as I’ve long said, <b>if you can’t beat ’em, you might as well join</b>. If the world’s richest man generated an extra $75 million along the way by using privileged information, isn’t it fair to follow his steps?</p><p>It’s a strategy I’ve called the <b>Insider Track</b>.</p><h2>The Best Time to Buy… Is in a Bear Market</h2><p>The Insider Track strategy has provenly strong results. Since January 2009, C-Suite buying has generated an annualized return of 20.8%, according to tracking site TipRanks. And in the past week alone, insiders have snapped up $45 million of their corporate shares.</p><p>These amounts are admittedly smaller than in previous declines. In May 2020, insiders bought a stunning $161 million of shares after the Covid-19 slump. And today, many sectors are doing worse than in 2020 because of higher inflation and rising rates.</p><p>But some American businesses are still humming along. Here are 15 stocks where insiders act as if they know something the market doesn’t.</p><h2>Top Market Timers</h2><p>One of the best <b>Insider Track</b> strategies involves mimicking the trades of particularly successful insiders. These are investment firms, CEOs and company owners that have an unusual ability to buy the dips.</p><p><b>B. Riley Financial</b>. The boutique investment bank has a strong track record in trading the companies it owns.</p><ul><li><b>Lazydays Holdings</b> (NASDAQ:<b>LAZY</b>). In July, the investment bank bought over 10,000 LAZY shares in the $12 range before the CEO announced “remarkable performance” figures. Shares would jump to $17.50. Recent market wobbles have sent LAZY back to the $12 range – an opportunity B. Riley has used to add another 20,000 shares.</li></ul><p><b>Opaleye LLC</b>. Opaleye LLC has a notable record of picking biotech winners. A $16 million investment in <b>Travere Therapeutics</b> (NASDAQ:<b>TVTX</b>) in 2014 is now worth almost $50 million, and a smaller investment in <b><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a></b> (NASDAQ:<b>OCUL</b>) netted an even more significant 400% return in 2020. Now, the company has added shares in:</p><ul><li><b>TELA Bio</b> (NASDAQ:<b><u>TELA</u></b>). Since June, Opaleye has snapped up shares of TELA in the $5.75 to $8.25 range in seven transactions. The commercial-stage medical tech firm produces products for soft-tissue reconstruction in hernias, plastic and reconstructive surgery. The firm has a stable business, so Opaleye is likely buying as a valuation play.</li><li><b>TRACON Pharmaceuticals</b> (NASDAQ:<b>TCON</b>). The biotech research firm is developing an oncology drug that targets the PD-L1 antibody, a known pathway under study by other large cancer research firms. The drug is now in its pivotal Phase 2 trial, giving the stock a significant upside on any good news.</li><li><b>Protara Therapeutics</b> (NASDAQ:<b>TARA</b>). The New York-based biopharma company has two development programs in its pipeline. OK-432 is designed to treat lymphatic malformations, a common disease thought to affect 1 in every 4,000 live births, and TARA-002, a treatment for bladder cancer. Opaleye’s 19,400 share addition in mid-September brings its stake to 2,575,77, a significant stake in a company with potential blockbusters in its pipeline.</li></ul><h3>Biotech Stocks</h3><p>Opaleye’s investments represent bets on biotech — some of the hardest decisions for the <b>Insider Track</b> strategy. Many of these R&amp;D firms are riding on a single drug candidate, meaning one failed trial will send the stock to zero. And as outsiders, we can’t tell the difference between opportunistic insider buying versus “pump and dumps.”</p><p><i>But biotechs are also some of the most lucrative bets, as Longeveron shows.</i></p><p>That’s because biotech executives often know clinical trial results years before the studies publish official results. If half of your patients suddenly stop developing cancers, you don’t need to be a rocket scientist (or a biotech CEO) to realize your therapy is probably outperforming the placebo in your double-blind study. These executives are also generally aware of how discussions with healthcare regulators are progressing.</p><p>That leads us to three biotech stocks where insiders have recently bought significant stakes.</p><p><b>Zivo Bioscience</b> (NASDAQ:<b>ZIVO</b>). Director Christopher Maggiore joined CEO John Payne in buying shares in the $3.50 range after shares fell from over $5. The company develops algae-based products for food-based ingredients and has a market value of under $30 million. It’s a risky bet, but Mr. Maggiore’s $25,000 share purchase suggests he knows something we don’t.</p><p><b><a href=\"https://laohu8.com/S/BTTX\">Better Therapeutics</a></b> (NASDAQ:<b>BTTX</b>). The prescription digital therapeutics firm has seen a recent rash of cluster buying. The company’s CEO, CFO and a 10% owner have added $304,000 to their stakes since Sept. 12, a telling sign that the firm might have stumbled on a working therapy. Management previously indicated that its most promising candidate, BT-001, could advance pivotal trials this year or early 2023. Trades centered in the $2 range.</p><p><b>TransCode Therapeutics</b> (NASDAQ:<b>RNAZ</b>). The firm’s CEO and 10% owner added 20,000 shares on Sept. 14, raising his stake to 893,114 shares. The firm has a single therapeutic candidate, TTDX-MC138, in its pipeline designed to treat metastatic cancer. The drug is in preclinical trials, meaning that any good news could send shares up several times over.</p><h2>Insider Purchases of Public Offerings</h2><p>Public offerings are one of the best ways to understand insider sentiment. Management can spend months preparing these offerings, giving them a clear idea of the issue’s true value as Elon Musk demonstrated in his 2019 TSLA purchase.</p><p><b>Larimar Therapeutics</b> (NASDAQ:<b>LRMR</b>). The biotech’s CEO, CFO and two directors bought a combined 5.1 million shares at the firm’s public offering price of $3.15. Larimar’s lead candidate CTI-1601 is currently undergoing Phase 1 clinical trials for Friedreich’s ataxia, a rare genetic disease. Shares would jump 15.5% the following day after the FDA lifted a hold on the trial, but such broad insider purchasing often indicates more potential gains.</p><p><b>LinkBancorp</b> (NASDAQ:<b><u>LNKB</u></b>). The Pennsylvania-based bank saw 17 executives and directors buy shares in its recent $7.50 public offer – the same price it offered public investors. One director added 80,000 shares in the $7.70 range after prices jumped in first-day trading. Though outsiders won’t get a clear look into the bank’s recent merger with Gratz until next quarter, insiders seem to believe there’s no need to wait for official pro forma figures to buy at market prices.</p><h2>Cluster Buying</h2><p>Finally, corporate executives often act together in buying company shares. These are some of the most compelling <b>Insider Track</b> investments to make.</p><p><b>Macerich</b> (NYSE:<b>MAC</b>). The Santa Monica-based homebuilder saw six insiders buy 104,617 shares this week, including the company’s CEO, president, CFO, and head of leasing. The company now trades at 0.6x book value, significantly below its historical average of 1.6x.</p><p><b>Liquidia</b> (NASDAQ:<b>LQDA</b>). Shares of the biopharmaceutical company sank 37% in late August after losing a patent battle with <b>United Therapeutics</b> (NASDAQ:<b>UTHR</b>) Insiders, however, have recently bought shares in the $5.50-$6.00 range, including its CEO (45,747 shares), CFO (8000 shares), Commercial SVP (2,160 shares), COO (1,918 shares) and 10% owner <b>Caligan Partners</b> (250,000 shares).</p><p><b><a href=\"https://laohu8.com/S/MFA\">MFA Financial</a></b> (NYSE:<b>MFA</b>). Between Sept. 14-15, the financial firm’s CEO, CFO, Co-CIO and a director added over 10,000 shares to their already-substantial holdings. Shares of MFA have fallen 55% this year over fears about its lending portfolio, particularly from its high exposure to residential whole loans. Insiders are buying shares as if the worries are wildly overblown.</p><p><b>B. Riley Financial</b> (NASDAQ:<b>RILY</b>). The company’s CEO Andrew Moore and director Randall Paulson joined owner Bryant Riley this week in snapping up a combined 48,400 shares in the boutique investment banking and wealth management firm. Shares currently trade at under 6x price-earnings, making it one of the cheapest investment banks by that metric.</p><p><b>Tilly’s</b> (NYSE:<b>TLYS</b>). The CFO of the youth-oriented shoe and clothing retailer joined two directors this week in buying up shares in the $6-$7 range. Tilly’s recent share slide now prices the retailer at 1.5x EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation and amortization), around a quarter of its usual value. Given its high operating leverage, a stronger-than-expected back-to-school season could send shares up 2x-3x from current prices.</p><p><b>L. B. Foster</b> (NASDAQ:<b>FSTR</b>). The CEO and CFO of the railroad infrastructure firm bought another 4,000 shares on Sept. 13, increasing their combined stake to over 110,000. The company trades for under 0.6x price-book, its lowest valuation since February 2016. The last time that happened, shares would recover within two months, earning investors a 60% return within two months and another 30% return within the next 10.</p><h2>Conclusion: How to Use the Insider Track</h2><p>Not all insider purchases are created equal.</p><p>Some industries like biotech, metals and mining are a treasure trove of opportunity. Executives are often aware of promising new drugs and dig sites long before the companies are required by the SEC to disclose material findings.</p><p>Following executives in other sectors comes with greater risks. Are insiders at <b>Exxon</b> (NYSE:<b>XOM</b>) buying because of an unannounced deal? Or are they blindly speculating on oil prices instead?</p><p>That’s why I tend to avoid companies like <b>HighPeak Energy</b> (NASDAQ:<b>HPK</b>), <b>U.S. Energy Corp</b> (NASDAQ:<b>USEG</b>) and <b>Stronghold Digital Mining</b> (NASDAQ:<b>SDIG</b>) — firms that also recently announced insider purchases. Shares in these firms more closely track the price of oil and <b>Bitcoin</b> (<b><u>BTC-USD</u></b>) – assets that no executive can predict.</p><p>Instead, I focus on bets with particularly opaque financials and high operating leverage. And though every investment requires deeper research before jumping in, the <b>Insider Track</b> provides us with a strong starting point to beating the markets.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsider Buying 2022: 15 Stocks to Bet On Despite the Bear Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-07 10:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech firm working on a promising Alzheimer’s therapy.Within six weeks, shares had risen over 11x… a ...</p>\n\n<a href=\"https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4094":"服装零售","PSQ":"纳指反向ETF","MFA":"MFA Financial","BTTX":"Better Therapeutics","BK4110":"抵押房地产投资信托","TLYS":"Tilly’s","BK4099":"汽车制造商","BK4511":"特斯拉概念","BK4183":"个人用品","XOM":"埃克森美孚","BK4127":"投资银行业与经纪业","TQQQ":"纳指三倍做多ETF","USEG":"美国能源","MAC":"马塞里奇房产","BK4213":"石油与天然气的勘探与生产","RILY":"B. Riley Financial, Inc.",".IXIC":"NASDAQ Composite","BK4539":"次新股","QLD":"纳指两倍做多ETF","BK4516":"特朗普概念","BK4023":"应用软件","LQDA":"Liquidia Technologies Inc","ZIVO":"Zivo Bioscience, Inc.","TELA":"TELA Bio, Inc.","QQQ":"纳指100ETF","BK4532":"文艺复兴科技持仓","BK4570":"地缘局势概念股","SQQQ":"纳指三倍做空ETF","BK4214":"汽车零售","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4139":"生物科技","TVTX":"Travere Therapeutics, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","RNAZ":"TransCode Therapeutics  Inc.","OCUL":"Ocular Therapeutix","BK4080":"零售业房地产投资信托","SDIG":"Stronghold Digital Mining, Inc","FSTR":"LB福斯特","BK4167":"医疗保健技术","BK4527":"明星科技股","LRMR":"Larimar Therapeutics, Inc.","HPK":"Highpeak Energy Acquisition Corp","TARA":"ArTara Therapeutics, Inc.","BK4551":"寇图资本持仓","BK4198":"医疗保健用品","TSLA":"特斯拉","BK4574":"无人驾驶"},"source_url":"https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2273828361","content_text":"Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech firm working on a promising Alzheimer’s therapy.Within six weeks, shares had risen over 11x… a stunning 1,000% return!My secret?I noticed that the biotech’s CFO was quietly buying shares in the company.“With clinical results due within the next month, Longeveron’s executives are likely using their knowledge of the Aging Frailty study to predict a strong outcome in the Alzheimer’s trial.”Just a month later, the company would announce some unexpectedly good news: The U.S. Food and Drug Administration (FDA) approved Longeveron’s Lomecel-B for use!The Secret to Finding 1,000% WinnersIt turns out that Longeveron’s management aren’t the only ones who are suspiciously good at timing their company’s stock.A study by MIT researchers found that insider transactions in the U.S. would have turned $10,000 into $156,000 over their study period, compared to around $50,300 in the S&P 500.That’s because insiders often act on privileged information, both knowingly and unknowingly. If sales figures are doing well… or patients are responding well to clinical trials… they don’t need the “official” SEC filings to decide to buy.Some call it a total scam.And I get it. SEC rules around insider transactions are surprisingly lax; if a CEO sees a new product performing well or is on the cusp of making a massive deal, it’s often entirely legal to trade on that information. In 2018, Tesla (NASDAQ:TSLA) CEO Elon Musk bought $25 million of his company’s shares while details of a massive $2 billion capital raise were still under wraps.TSLA shares would rise 206% within a year.But as I’ve long said, if you can’t beat ’em, you might as well join. If the world’s richest man generated an extra $75 million along the way by using privileged information, isn’t it fair to follow his steps?It’s a strategy I’ve called the Insider Track.The Best Time to Buy… Is in a Bear MarketThe Insider Track strategy has provenly strong results. Since January 2009, C-Suite buying has generated an annualized return of 20.8%, according to tracking site TipRanks. And in the past week alone, insiders have snapped up $45 million of their corporate shares.These amounts are admittedly smaller than in previous declines. In May 2020, insiders bought a stunning $161 million of shares after the Covid-19 slump. And today, many sectors are doing worse than in 2020 because of higher inflation and rising rates.But some American businesses are still humming along. Here are 15 stocks where insiders act as if they know something the market doesn’t.Top Market TimersOne of the best Insider Track strategies involves mimicking the trades of particularly successful insiders. These are investment firms, CEOs and company owners that have an unusual ability to buy the dips.B. Riley Financial. The boutique investment bank has a strong track record in trading the companies it owns.Lazydays Holdings (NASDAQ:LAZY). In July, the investment bank bought over 10,000 LAZY shares in the $12 range before the CEO announced “remarkable performance” figures. Shares would jump to $17.50. Recent market wobbles have sent LAZY back to the $12 range – an opportunity B. Riley has used to add another 20,000 shares.Opaleye LLC. Opaleye LLC has a notable record of picking biotech winners. A $16 million investment in Travere Therapeutics (NASDAQ:TVTX) in 2014 is now worth almost $50 million, and a smaller investment in Ocular Therapeutix (NASDAQ:OCUL) netted an even more significant 400% return in 2020. Now, the company has added shares in:TELA Bio (NASDAQ:TELA). Since June, Opaleye has snapped up shares of TELA in the $5.75 to $8.25 range in seven transactions. The commercial-stage medical tech firm produces products for soft-tissue reconstruction in hernias, plastic and reconstructive surgery. The firm has a stable business, so Opaleye is likely buying as a valuation play.TRACON Pharmaceuticals (NASDAQ:TCON). The biotech research firm is developing an oncology drug that targets the PD-L1 antibody, a known pathway under study by other large cancer research firms. The drug is now in its pivotal Phase 2 trial, giving the stock a significant upside on any good news.Protara Therapeutics (NASDAQ:TARA). The New York-based biopharma company has two development programs in its pipeline. OK-432 is designed to treat lymphatic malformations, a common disease thought to affect 1 in every 4,000 live births, and TARA-002, a treatment for bladder cancer. Opaleye’s 19,400 share addition in mid-September brings its stake to 2,575,77, a significant stake in a company with potential blockbusters in its pipeline.Biotech StocksOpaleye’s investments represent bets on biotech — some of the hardest decisions for the Insider Track strategy. Many of these R&D firms are riding on a single drug candidate, meaning one failed trial will send the stock to zero. And as outsiders, we can’t tell the difference between opportunistic insider buying versus “pump and dumps.”But biotechs are also some of the most lucrative bets, as Longeveron shows.That’s because biotech executives often know clinical trial results years before the studies publish official results. If half of your patients suddenly stop developing cancers, you don’t need to be a rocket scientist (or a biotech CEO) to realize your therapy is probably outperforming the placebo in your double-blind study. These executives are also generally aware of how discussions with healthcare regulators are progressing.That leads us to three biotech stocks where insiders have recently bought significant stakes.Zivo Bioscience (NASDAQ:ZIVO). Director Christopher Maggiore joined CEO John Payne in buying shares in the $3.50 range after shares fell from over $5. The company develops algae-based products for food-based ingredients and has a market value of under $30 million. It’s a risky bet, but Mr. Maggiore’s $25,000 share purchase suggests he knows something we don’t.Better Therapeutics (NASDAQ:BTTX). The prescription digital therapeutics firm has seen a recent rash of cluster buying. The company’s CEO, CFO and a 10% owner have added $304,000 to their stakes since Sept. 12, a telling sign that the firm might have stumbled on a working therapy. Management previously indicated that its most promising candidate, BT-001, could advance pivotal trials this year or early 2023. Trades centered in the $2 range.TransCode Therapeutics (NASDAQ:RNAZ). The firm’s CEO and 10% owner added 20,000 shares on Sept. 14, raising his stake to 893,114 shares. The firm has a single therapeutic candidate, TTDX-MC138, in its pipeline designed to treat metastatic cancer. The drug is in preclinical trials, meaning that any good news could send shares up several times over.Insider Purchases of Public OfferingsPublic offerings are one of the best ways to understand insider sentiment. Management can spend months preparing these offerings, giving them a clear idea of the issue’s true value as Elon Musk demonstrated in his 2019 TSLA purchase.Larimar Therapeutics (NASDAQ:LRMR). The biotech’s CEO, CFO and two directors bought a combined 5.1 million shares at the firm’s public offering price of $3.15. Larimar’s lead candidate CTI-1601 is currently undergoing Phase 1 clinical trials for Friedreich’s ataxia, a rare genetic disease. Shares would jump 15.5% the following day after the FDA lifted a hold on the trial, but such broad insider purchasing often indicates more potential gains.LinkBancorp (NASDAQ:LNKB). The Pennsylvania-based bank saw 17 executives and directors buy shares in its recent $7.50 public offer – the same price it offered public investors. One director added 80,000 shares in the $7.70 range after prices jumped in first-day trading. Though outsiders won’t get a clear look into the bank’s recent merger with Gratz until next quarter, insiders seem to believe there’s no need to wait for official pro forma figures to buy at market prices.Cluster BuyingFinally, corporate executives often act together in buying company shares. These are some of the most compelling Insider Track investments to make.Macerich (NYSE:MAC). The Santa Monica-based homebuilder saw six insiders buy 104,617 shares this week, including the company’s CEO, president, CFO, and head of leasing. The company now trades at 0.6x book value, significantly below its historical average of 1.6x.Liquidia (NASDAQ:LQDA). Shares of the biopharmaceutical company sank 37% in late August after losing a patent battle with United Therapeutics (NASDAQ:UTHR) Insiders, however, have recently bought shares in the $5.50-$6.00 range, including its CEO (45,747 shares), CFO (8000 shares), Commercial SVP (2,160 shares), COO (1,918 shares) and 10% owner Caligan Partners (250,000 shares).MFA Financial (NYSE:MFA). Between Sept. 14-15, the financial firm’s CEO, CFO, Co-CIO and a director added over 10,000 shares to their already-substantial holdings. Shares of MFA have fallen 55% this year over fears about its lending portfolio, particularly from its high exposure to residential whole loans. Insiders are buying shares as if the worries are wildly overblown.B. Riley Financial (NASDAQ:RILY). The company’s CEO Andrew Moore and director Randall Paulson joined owner Bryant Riley this week in snapping up a combined 48,400 shares in the boutique investment banking and wealth management firm. Shares currently trade at under 6x price-earnings, making it one of the cheapest investment banks by that metric.Tilly’s (NYSE:TLYS). The CFO of the youth-oriented shoe and clothing retailer joined two directors this week in buying up shares in the $6-$7 range. Tilly’s recent share slide now prices the retailer at 1.5x EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation and amortization), around a quarter of its usual value. Given its high operating leverage, a stronger-than-expected back-to-school season could send shares up 2x-3x from current prices.L. B. Foster (NASDAQ:FSTR). The CEO and CFO of the railroad infrastructure firm bought another 4,000 shares on Sept. 13, increasing their combined stake to over 110,000. The company trades for under 0.6x price-book, its lowest valuation since February 2016. The last time that happened, shares would recover within two months, earning investors a 60% return within two months and another 30% return within the next 10.Conclusion: How to Use the Insider TrackNot all insider purchases are created equal.Some industries like biotech, metals and mining are a treasure trove of opportunity. Executives are often aware of promising new drugs and dig sites long before the companies are required by the SEC to disclose material findings.Following executives in other sectors comes with greater risks. Are insiders at Exxon (NYSE:XOM) buying because of an unannounced deal? Or are they blindly speculating on oil prices instead?That’s why I tend to avoid companies like HighPeak Energy (NASDAQ:HPK), U.S. Energy Corp (NASDAQ:USEG) and Stronghold Digital Mining (NASDAQ:SDIG) — firms that also recently announced insider purchases. Shares in these firms more closely track the price of oil and Bitcoin (BTC-USD) – assets that no executive can predict.Instead, I focus on bets with particularly opaque financials and high operating leverage. And though every investment requires deeper research before jumping in, the Insider Track provides us with a strong starting point to beating the markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":265396300406912,"gmtCreate":1705818058033,"gmtModify":1705818062018,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a> go go go","text":"$Tesla Motors(TSLA)$ go go go","images":[{"img":"https://community-static.tradeup.com/news/66c6acbdf68373dd06c0fc027420b4bd","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/265396300406912","isVote":1,"tweetType":1,"viewCount":424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9981575285,"gmtCreate":1666575534948,"gmtModify":1676537769707,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>go go go","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>go go go","text":"$Tesla Motors(TSLA)$go go go","images":[{"img":"https://community-static.tradeup.com/news/5c13289c8a69826c36bddd56fc9f669a","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9981575285","isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9988329721,"gmtCreate":1666670982363,"gmtModify":1676537787465,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>fml worng time","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>fml worng time","text":"$DiDi Global Inc.(DIDIY)$fml worng time","images":[{"img":"https://community-static.tradeup.com/news/e1ed96aa3b9dc2838c98488bdd0a880b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988329721","isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9999883292,"gmtCreate":1660519475718,"gmtModify":1676533482276,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>omg","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>omg","text":"$DiDi Global Inc.(DIDIY)$omg","images":[{"img":"https://community-static.tradeup.com/news/9d015d8cf0bc89d7bbc721227f3f7aa8","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9999883292","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9990468736,"gmtCreate":1660397423927,"gmtModify":1676533464380,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>omg","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$</a>omg","text":"$DiDi Global Inc.(DIDIY)$omg","images":[{"img":"https://community-static.tradeup.com/news/9d015d8cf0bc89d7bbc721227f3f7aa8","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9990468736","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9902752563,"gmtCreate":1659757145154,"gmtModify":1703766333691,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>pray","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>pray","text":"$Meta Platforms, Inc.(META)$pray","images":[{"img":"https://community-static.tradeup.com/news/8aec147d1a10c9b2c116287416ba7dfb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902752563","isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9906603186,"gmtCreate":1659529036648,"gmtModify":1705981271538,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906603186","repostId":"1191048104","repostType":4,"repost":{"id":"1191048104","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1659528098,"share":"https://www.laohu8.com/m/news/1191048104?lang=&edition=full","pubTime":"2022-08-03 20:01","market":"us","language":"en","title":"Pre-Bell｜U.S. Stock Index Futures Rise; PayPal Stock Surges 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191048104","media":"Tiger Newspress","summary":"U.S. stock index futures edged higher on Wednesday, with focus on services activity data due later i","content":"<html><head></head><body><p>U.S. stock index futures edged higher on Wednesday, with focus on services activity data due later in the day after a report earlier this week amplified economic slowdown worries, while PayPal gained on raising its profit forecast.</p><h2><b>Market Snapshot</b></h2><p>At 8:00 a.m. ET, Dow e-minis were up 138 points, or 0.43%, S&amp;P 500 e-minis were up 19 points, or 0.46%, and Nasdaq 100 e-minis were up 59.75 points, or 0.46%.</p><p><img src=\"https://static.tigerbbs.com/290b6deff2457789d7a5af7f6552025b\" tg-width=\"500\" tg-height=\"228\" referrerpolicy=\"no-referrer\"/></p><h2><b>Pre-Market Movers</b></h2><p>CVS Health (CVS) – The drug store operator and pharmacy benefits manager saw its shares rise 3.8% in the premarket afterbeating top- and bottom-line estimatesand raising its full-year earnings forecast.  Results were helped by strong sales of over-the-counter Covid-19 tests as well as an upbeat performance by its insurance unit.</p><p>Under Armour(UAA) – The athletic apparel maker gained 2% in premarket action despite cutting its full-year earnings forecast. Increased promotional activity and currency headwinds have impacted Under Armour&#39;s profit margins, but it did report earnings for its most recent quarter that matched estimates and revenue that was slightly ahead of consensus.</p><p>Moderna(MRNA) – The vaccine maker reported better-than-expected profit and revenue for its latest quarter and also announced a $3 billion share repurchase program. Moderna also maintained its full-year sales outlook, and its stock gained 2.6% in premarket action.</p><p>Starbucks(SBUX) – Starbucks shares rose 1.8% in the premarket after it reported better-than-expected quarterly profit and revenue. Global comparable store sales did come in below forecasts, however, due to weakness in the locked-down China market.</p><p>Sierra Wireless(SWIR) – The provider of connectivity technology agreed to be acquired by Canadian semiconductor makerSemtechfor $31 per share in cash or $1.2 billion. Sierra Wireless surged 7.8% in the premarket, while Semtech shares fell 1.5%.</p><p>Dish Network(DISH) – The satellite TV company added 1.3% in premarket trading after reporting better-than-expected quarterly earnings. The bottom-line beat came despite a slight revenue miss and the loss of 257,000 pay TV subscribers during the quarter.</p><p>SoFi(SOFI) – The fintech company&#39;s stock soared 10.9% in premarket action after it reported a smaller-than-expected loss and better-than-expected revenue. It also issued strong full-year revenue guidance. Results were helped by a 91% jump in personal loan origination volume.</p><p>Match Group(MTCH) – Shares of the dating service operator tumbled 21.4% in the premarket after it reported lower-than-expected quarterly results and said top-line growth would be flat during the second half of the year. Match also announced the departure of Renate Nyborg, CEO of its Tinder unit.</p><p>Airbnb(ABNB) – Airbnb reported better-than-expected quarterly earnings with its revenue essentially in line, as travel demand boomed. However, the stock slid 7.3% in premarket trading after it issued a lighter-than-expected bookings forecast for the current quarter.</p><h2><b>Market News</b></h2><h3>Uber Sells 7.8% Stake in India&#39;s Zomato for $392 Million</h3><p><a href=\"https://laohu8.com/S/UBER\">Uber Technologies</a> on Wednesday sold its 7.8% stake in Indian food delivery firm Zomato Ltd for $392 million via a block trade on local exchanges, two sources familiar with the matter told Reuters.</p><p>The deal was executed at 50.44 rupees per share, they said.</p><h3>Yum Shares Slid Premarket After Q2 Earnings Fall Short of Estimates</h3><p>Yum Brands Inc. <a href=\"https://laohu8.com/S/YUM\">$(YUM)$</a> posted weaker-than-expected second-quarter earnings on Wednesday, and sales that fell short of forecasts, sending the stock lower premarket.</p><p>The company had net income of $224 million, or 77 cents a share, for the quarter, down from $391 million, or $1.29 a share, in the year-earlier period.</p><h3>Regeneron Quarterly Profit Slips As COVID Antibody Sales Dry up</h3><p>Regeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lacklustre sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit its use earlier this year.</p><p>The drugmaker&#39;s net profit fell to $852 million, or $7.47 per share, in the second quarter ended June 30, compared with $3.1 billion, or $27.97 per share, a year earlier.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pre-Bell｜U.S. Stock Index Futures Rise; PayPal Stock Surges 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPre-Bell｜U.S. Stock Index Futures Rise; PayPal Stock Surges 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-08-03 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures edged higher on Wednesday, with focus on services activity data due later in the day after a report earlier this week amplified economic slowdown worries, while PayPal gained on raising its profit forecast.</p><h2><b>Market Snapshot</b></h2><p>At 8:00 a.m. ET, Dow e-minis were up 138 points, or 0.43%, S&amp;P 500 e-minis were up 19 points, or 0.46%, and Nasdaq 100 e-minis were up 59.75 points, or 0.46%.</p><p><img src=\"https://static.tigerbbs.com/290b6deff2457789d7a5af7f6552025b\" tg-width=\"500\" tg-height=\"228\" referrerpolicy=\"no-referrer\"/></p><h2><b>Pre-Market Movers</b></h2><p>CVS Health (CVS) – The drug store operator and pharmacy benefits manager saw its shares rise 3.8% in the premarket afterbeating top- and bottom-line estimatesand raising its full-year earnings forecast.  Results were helped by strong sales of over-the-counter Covid-19 tests as well as an upbeat performance by its insurance unit.</p><p>Under Armour(UAA) – The athletic apparel maker gained 2% in premarket action despite cutting its full-year earnings forecast. Increased promotional activity and currency headwinds have impacted Under Armour&#39;s profit margins, but it did report earnings for its most recent quarter that matched estimates and revenue that was slightly ahead of consensus.</p><p>Moderna(MRNA) – The vaccine maker reported better-than-expected profit and revenue for its latest quarter and also announced a $3 billion share repurchase program. Moderna also maintained its full-year sales outlook, and its stock gained 2.6% in premarket action.</p><p>Starbucks(SBUX) – Starbucks shares rose 1.8% in the premarket after it reported better-than-expected quarterly profit and revenue. Global comparable store sales did come in below forecasts, however, due to weakness in the locked-down China market.</p><p>Sierra Wireless(SWIR) – The provider of connectivity technology agreed to be acquired by Canadian semiconductor makerSemtechfor $31 per share in cash or $1.2 billion. Sierra Wireless surged 7.8% in the premarket, while Semtech shares fell 1.5%.</p><p>Dish Network(DISH) – The satellite TV company added 1.3% in premarket trading after reporting better-than-expected quarterly earnings. The bottom-line beat came despite a slight revenue miss and the loss of 257,000 pay TV subscribers during the quarter.</p><p>SoFi(SOFI) – The fintech company&#39;s stock soared 10.9% in premarket action after it reported a smaller-than-expected loss and better-than-expected revenue. It also issued strong full-year revenue guidance. Results were helped by a 91% jump in personal loan origination volume.</p><p>Match Group(MTCH) – Shares of the dating service operator tumbled 21.4% in the premarket after it reported lower-than-expected quarterly results and said top-line growth would be flat during the second half of the year. Match also announced the departure of Renate Nyborg, CEO of its Tinder unit.</p><p>Airbnb(ABNB) – Airbnb reported better-than-expected quarterly earnings with its revenue essentially in line, as travel demand boomed. However, the stock slid 7.3% in premarket trading after it issued a lighter-than-expected bookings forecast for the current quarter.</p><h2><b>Market News</b></h2><h3>Uber Sells 7.8% Stake in India&#39;s Zomato for $392 Million</h3><p><a href=\"https://laohu8.com/S/UBER\">Uber Technologies</a> on Wednesday sold its 7.8% stake in Indian food delivery firm Zomato Ltd for $392 million via a block trade on local exchanges, two sources familiar with the matter told Reuters.</p><p>The deal was executed at 50.44 rupees per share, they said.</p><h3>Yum Shares Slid Premarket After Q2 Earnings Fall Short of Estimates</h3><p>Yum Brands Inc. <a href=\"https://laohu8.com/S/YUM\">$(YUM)$</a> posted weaker-than-expected second-quarter earnings on Wednesday, and sales that fell short of forecasts, sending the stock lower premarket.</p><p>The company had net income of $224 million, or 77 cents a share, for the quarter, down from $391 million, or $1.29 a share, in the year-earlier period.</p><h3>Regeneron Quarterly Profit Slips As COVID Antibody Sales Dry up</h3><p>Regeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lacklustre sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit its use earlier this year.</p><p>The drugmaker&#39;s net profit fell to $852 million, or $7.47 per share, in the second quarter ended June 30, compared with $3.1 billion, or $27.97 per share, a year earlier.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191048104","content_text":"U.S. stock index futures edged higher on Wednesday, with focus on services activity data due later in the day after a report earlier this week amplified economic slowdown worries, while PayPal gained on raising its profit forecast.Market SnapshotAt 8:00 a.m. ET, Dow e-minis were up 138 points, or 0.43%, S&P 500 e-minis were up 19 points, or 0.46%, and Nasdaq 100 e-minis were up 59.75 points, or 0.46%.Pre-Market MoversCVS Health (CVS) – The drug store operator and pharmacy benefits manager saw its shares rise 3.8% in the premarket afterbeating top- and bottom-line estimatesand raising its full-year earnings forecast.  Results were helped by strong sales of over-the-counter Covid-19 tests as well as an upbeat performance by its insurance unit.Under Armour(UAA) – The athletic apparel maker gained 2% in premarket action despite cutting its full-year earnings forecast. Increased promotional activity and currency headwinds have impacted Under Armour's profit margins, but it did report earnings for its most recent quarter that matched estimates and revenue that was slightly ahead of consensus.Moderna(MRNA) – The vaccine maker reported better-than-expected profit and revenue for its latest quarter and also announced a $3 billion share repurchase program. Moderna also maintained its full-year sales outlook, and its stock gained 2.6% in premarket action.Starbucks(SBUX) – Starbucks shares rose 1.8% in the premarket after it reported better-than-expected quarterly profit and revenue. Global comparable store sales did come in below forecasts, however, due to weakness in the locked-down China market.Sierra Wireless(SWIR) – The provider of connectivity technology agreed to be acquired by Canadian semiconductor makerSemtechfor $31 per share in cash or $1.2 billion. Sierra Wireless surged 7.8% in the premarket, while Semtech shares fell 1.5%.Dish Network(DISH) – The satellite TV company added 1.3% in premarket trading after reporting better-than-expected quarterly earnings. The bottom-line beat came despite a slight revenue miss and the loss of 257,000 pay TV subscribers during the quarter.SoFi(SOFI) – The fintech company's stock soared 10.9% in premarket action after it reported a smaller-than-expected loss and better-than-expected revenue. It also issued strong full-year revenue guidance. Results were helped by a 91% jump in personal loan origination volume.Match Group(MTCH) – Shares of the dating service operator tumbled 21.4% in the premarket after it reported lower-than-expected quarterly results and said top-line growth would be flat during the second half of the year. Match also announced the departure of Renate Nyborg, CEO of its Tinder unit.Airbnb(ABNB) – Airbnb reported better-than-expected quarterly earnings with its revenue essentially in line, as travel demand boomed. However, the stock slid 7.3% in premarket trading after it issued a lighter-than-expected bookings forecast for the current quarter.Market NewsUber Sells 7.8% Stake in India's Zomato for $392 MillionUber Technologies on Wednesday sold its 7.8% stake in Indian food delivery firm Zomato Ltd for $392 million via a block trade on local exchanges, two sources familiar with the matter told Reuters.The deal was executed at 50.44 rupees per share, they said.Yum Shares Slid Premarket After Q2 Earnings Fall Short of EstimatesYum Brands Inc. $(YUM)$ posted weaker-than-expected second-quarter earnings on Wednesday, and sales that fell short of forecasts, sending the stock lower premarket.The company had net income of $224 million, or 77 cents a share, for the quarter, down from $391 million, or $1.29 a share, in the year-earlier period.Regeneron Quarterly Profit Slips As COVID Antibody Sales Dry upRegeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lacklustre sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit its use earlier this year.The drugmaker's net profit fell to $852 million, or $7.47 per share, in the second quarter ended June 30, compared with $3.1 billion, or $27.97 per share, a year earlier.","news_type":1},"isVote":1,"tweetType":1,"viewCount":7,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9908809617,"gmtCreate":1659350108640,"gmtModify":1705979374071,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>buy or not buy?","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>buy or not buy?","text":"$Palantir Technologies Inc.(PLTR)$buy or not buy?","images":[{"img":"https://community-static.tradeup.com/news/0807482d07db1ed7ff756dd88e3f2bf4","width":"1080","height":"3288"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9908809617","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9909448599,"gmtCreate":1658914687911,"gmtModify":1676536228184,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9909448599","repostId":"1118051421","repostType":4,"repost":{"id":"1118051421","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1658909342,"share":"https://www.laohu8.com/m/news/1118051421?lang=&edition=full","pubTime":"2022-07-27 16:09","market":"us","language":"en","title":"Alphabet Shares Jumped 4.57% as Search Ads Topping Wall Street Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1118051421","media":"Tiger Newspress","summary":"Alphabet shares jumped 4.57% as search ads topping wall street targets.Google parent Alphabet Inc on","content":"<html><head></head><body><p>Alphabet shares jumped 4.57% as search ads topping wall street targets.<img src=\"https://static.tigerbbs.com/a1273be77f6d088994f6cf06f49db3cd\" tg-width=\"845\" tg-height=\"824\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Google parent Alphabet Inc on Tuesday posted quarterly sales close to Wall Street targets, sending shares up on relief that the world&#39;s biggest seller of online advertising had avoided the deep disappointment of rivals including Snap.</p><p>Sales from Google&#39;s search ad business actually topped expectations, while revenue from YouTube ads, cloud computing and Alphabet&#39;s &#34;other bets&#34; unit all came in lower than anticipated, according to data from FactSet and Refinitiv.</p><p>Alphabet reported Q2 EPS of $1.21, $0.07 worse than the analyst estimate of $1.28. </p><p>Revenue for the quarter came in at $69.69 billion versus the consensus estimate of $70.04 billion.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alphabet Shares Jumped 4.57% as Search Ads Topping Wall Street Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphabet Shares Jumped 4.57% as Search Ads Topping Wall Street Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-07-27 16:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alphabet shares jumped 4.57% as search ads topping wall street targets.<img src=\"https://static.tigerbbs.com/a1273be77f6d088994f6cf06f49db3cd\" tg-width=\"845\" tg-height=\"824\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Google parent Alphabet Inc on Tuesday posted quarterly sales close to Wall Street targets, sending shares up on relief that the world&#39;s biggest seller of online advertising had avoided the deep disappointment of rivals including Snap.</p><p>Sales from Google&#39;s search ad business actually topped expectations, while revenue from YouTube ads, cloud computing and Alphabet&#39;s &#34;other bets&#34; unit all came in lower than anticipated, according to data from FactSet and Refinitiv.</p><p>Alphabet reported Q2 EPS of $1.21, $0.07 worse than the analyst estimate of $1.28. </p><p>Revenue for the quarter came in at $69.69 billion versus the consensus estimate of $70.04 billion.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOG":"谷歌","GOOGL":"谷歌A"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118051421","content_text":"Alphabet shares jumped 4.57% as search ads topping wall street targets.Google parent Alphabet Inc on Tuesday posted quarterly sales close to Wall Street targets, sending shares up on relief that the world's biggest seller of online advertising had avoided the deep disappointment of rivals including Snap.Sales from Google's search ad business actually topped expectations, while revenue from YouTube ads, cloud computing and Alphabet's \"other bets\" unit all came in lower than anticipated, according to data from FactSet and Refinitiv.Alphabet reported Q2 EPS of $1.21, $0.07 worse than the analyst estimate of $1.28. Revenue for the quarter came in at $69.69 billion versus the consensus estimate of $70.04 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915729962,"gmtCreate":1665111678156,"gmtModify":1676537559598,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>omg hai...","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>omg hai...","text":"$Meta Platforms, Inc.(META)$omg hai...","images":[{"img":"https://community-static.tradeup.com/news/4e0471fa9a70616976e358099f3707b3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9915729962","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9911015917,"gmtCreate":1664085676439,"gmtModify":1676537388931,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>pray hard","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>pray hard","text":"$Meta Platforms, Inc.(META)$pray hard","images":[{"img":"https://community-static.tradeup.com/news/8357a71bc448e8889389ba3df0b00d3c","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9911015917","isVote":1,"tweetType":1,"viewCount":54,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9999888667,"gmtCreate":1660519519061,"gmtModify":1676533482322,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a>bull","listText":"<a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a>bull","text":"$S&P 500(.SPX)$bull","images":[{"img":"https://community-static.tradeup.com/news/7e6c802dde296da1fc932a33bf96363b","width":"1080","height":"1578"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9999888667","isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9904614888,"gmtCreate":1660033581388,"gmtModify":1703477195936,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>go go go","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>go go go","text":"$Palantir Technologies Inc.(PLTR)$go go go","images":[{"img":"https://community-static.tradeup.com/news/6a5a3b1aafddf41bb03f5ed274b6eb53","width":"1080","height":"3288"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904614888","isVote":1,"tweetType":1,"viewCount":98,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4109461531395300","authorId":"4109461531395300","name":"mars_venus","avatar":"https://community-static.tradeup.com/news/ea793d9d9a87db218b2f1749bf6ddfee","crmLevel":2,"crmLevelSwitch":0},"content":"Up up up... all the way[Dollars][Dollars][Dollars]","text":"Up up up... all the way[Dollars][Dollars][Dollars]","html":"Up up up... all the way[Dollars][Dollars][Dollars]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9906601877,"gmtCreate":1659529184101,"gmtModify":1705981273329,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906601877","repostId":"1142299765","repostType":4,"repost":{"id":"1142299765","pubTimestamp":1659526857,"share":"https://www.laohu8.com/m/news/1142299765?lang=&edition=full","pubTime":"2022-08-03 19:40","market":"us","language":"en","title":"CVS Health Gains As All-Around Performance Drives Strong 2Q Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1142299765","media":"Seeking Alpha","summary":"CVS Health added 3.6% in the pre-market Wednesday after the pharmacy retailer posted a strong revenu","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/CVS\">CVS Health</a> added 3.6% in the pre-market Wednesday after the pharmacy retailer posted a strong revenue beat for 2Q 2022 and raised the earnings guidance for the year thanks to outperformance across its business segments.</p><p><img src=\"https://static.tigerbbs.com/4c2b9f5551cf6b093f34b30ff72f466a\" tg-width=\"820\" tg-height=\"720\" width=\"100%\" height=\"auto\"/></p><p>Beating Wall Street estimates by as much as ~$4.3B, the revenue for the quarter jumped ~11% YoY to $80.6B as Health Care Benefits Segment exceeded expectations to generate $22.8B revenue with ~11% YoY growth.</p><p>The medical benefit ratio dropped to 82.9% compared to 84.1% in the corresponding period last year, while medical membership grew by 922,000 members from the end of 2Q 2021 to 24.4M.</p><p>Revenue for the Pharmacy Services Segment also exceeded Street forecasts in adding $42.8B with ~11% YoY growth as total pharmacy claims processed jumped ~4% YoY.</p><p>Revenue from the Retail/LTC Segment stood at $26.3B to exceed the consensus with ~6% YoY growth as prescriptions filled on a 30-day equivalent basis gained 1.6% YoY and 4.6% YoY without the impact of COVID-19 vaccinations.</p><p>&#34;Despite a challenging economic environment, our differentiated business model helped drive strong results this quarter, with significant revenue growth across all of our business segments,” Chief Executive Karen S. Lynch said ahead of the earnings call today at 8:00 a.m. EST.</p><p>For 2022, CVS (CVS) raised adjusted EPS guidance to $8.40 - $8.60 ahead of the average Street forecasts of $8.36.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health Gains As All-Around Performance Drives Strong 2Q Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health Gains As All-Around Performance Drives Strong 2Q Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-03 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3865572-cvs-stock-gains-as-all-around-performance-drives-2q-beat><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CVS Health added 3.6% in the pre-market Wednesday after the pharmacy retailer posted a strong revenue beat for 2Q 2022 and raised the earnings guidance for the year thanks to outperformance across its...</p>\n\n<a href=\"https://seekingalpha.com/news/3865572-cvs-stock-gains-as-all-around-performance-drives-2q-beat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVS":"西维斯健康"},"source_url":"https://seekingalpha.com/news/3865572-cvs-stock-gains-as-all-around-performance-drives-2q-beat","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142299765","content_text":"CVS Health added 3.6% in the pre-market Wednesday after the pharmacy retailer posted a strong revenue beat for 2Q 2022 and raised the earnings guidance for the year thanks to outperformance across its business segments.Beating Wall Street estimates by as much as ~$4.3B, the revenue for the quarter jumped ~11% YoY to $80.6B as Health Care Benefits Segment exceeded expectations to generate $22.8B revenue with ~11% YoY growth.The medical benefit ratio dropped to 82.9% compared to 84.1% in the corresponding period last year, while medical membership grew by 922,000 members from the end of 2Q 2021 to 24.4M.Revenue for the Pharmacy Services Segment also exceeded Street forecasts in adding $42.8B with ~11% YoY growth as total pharmacy claims processed jumped ~4% YoY.Revenue from the Retail/LTC Segment stood at $26.3B to exceed the consensus with ~6% YoY growth as prescriptions filled on a 30-day equivalent basis gained 1.6% YoY and 4.6% YoY without the impact of COVID-19 vaccinations.\"Despite a challenging economic environment, our differentiated business model helped drive strong results this quarter, with significant revenue growth across all of our business segments,” Chief Executive Karen S. Lynch said ahead of the earnings call today at 8:00 a.m. EST.For 2022, CVS (CVS) raised adjusted EPS guidance to $8.40 - $8.60 ahead of the average Street forecasts of $8.36.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":299506467254432,"gmtCreate":1714141119772,"gmtModify":1714141125243,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> go go go","listText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> go go go","text":"$Alphabet(GOOGL)$ go go go","images":[{"img":"https://community-static.tradeup.com/news/40d83422b1fa384a85031ce6f750d06c","width":"894","height":"1508"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/299506467254432","isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9989546911,"gmtCreate":1666052375333,"gmtModify":1676537697196,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>to moon pls","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$</a>to moon pls","text":"$Meta Platforms, Inc.(META)$to moon pls","images":[{"img":"https://community-static.tradeup.com/news/e67a4cbbc235d8ae4a1aacda1bb6444b","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9989546911","isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9915720961,"gmtCreate":1665111550153,"gmtModify":1676537559572,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915720961","repostId":"2273828361","repostType":4,"repost":{"id":"2273828361","pubTimestamp":1665108107,"share":"https://www.laohu8.com/m/news/2273828361?lang=&edition=full","pubTime":"2022-10-07 10:01","market":"us","language":"en","title":"Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2273828361","media":"InvestorPlace","summary":"Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech ","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/11abc7bc1b026070774bd992fe8fb96d\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\"/></p><p>Source: Shutterstock</p><p>In October 2021, I made a big call on <b>Longeveron</b> (NASDAQ:<b>LGVN</b>) stock, a biotech firm working on a promising Alzheimer’s therapy.</p><p>Within six weeks, shares had risen over 11x… a stunning 1,000% return!</p><p>My secret?</p><p>I noticed that the biotech’s CFO was quietly buying shares in the company.</p><p>“With clinical results due within the next month, Longeveron’s executives are likely using their knowledge of the Aging Frailty study to predict a strong outcome in the Alzheimer’s trial.”</p><p>Just a month later, the company would announce some unexpectedly good news: The U.S. Food and Drug Administration (FDA) approved Longeveron’s Lomecel-B for use!</p><h2>The Secret to Finding 1,000% Winners</h2><p>It turns out that Longeveron’s management aren’t the only ones who are suspiciously good at timing their company’s stock.</p><p>A study by MIT researchers found that insider transactions in the U.S. would have turned $10,000 into $156,000 over their study period, compared to around $50,300 in the <b>S&amp;P 500</b>.</p><p>That’s because insiders often act on privileged information, both knowingly and unknowingly. If sales figures are doing well… or patients are responding well to clinical trials… they don’t need the “official” SEC filings to decide to buy.</p><p>Some call it a total scam.</p><p>And I get it. SEC rules around insider transactions are surprisingly lax; if a CEO sees a new product performing well or is on the cusp of making a massive deal, it’s often entirely legal to trade on that information. In 2018, <b>Tesla</b> (NASDAQ:<b>TSLA</b>) CEO Elon Musk bought $25 million of his company’s shares while details of a massive $2 billion capital raise were still under wraps.</p><p>TSLA shares would rise 206% within a year.</p><p>But as I’ve long said, <b>if you can’t beat ’em, you might as well join</b>. If the world’s richest man generated an extra $75 million along the way by using privileged information, isn’t it fair to follow his steps?</p><p>It’s a strategy I’ve called the <b>Insider Track</b>.</p><h2>The Best Time to Buy… Is in a Bear Market</h2><p>The Insider Track strategy has provenly strong results. Since January 2009, C-Suite buying has generated an annualized return of 20.8%, according to tracking site TipRanks. And in the past week alone, insiders have snapped up $45 million of their corporate shares.</p><p>These amounts are admittedly smaller than in previous declines. In May 2020, insiders bought a stunning $161 million of shares after the Covid-19 slump. And today, many sectors are doing worse than in 2020 because of higher inflation and rising rates.</p><p>But some American businesses are still humming along. Here are 15 stocks where insiders act as if they know something the market doesn’t.</p><h2>Top Market Timers</h2><p>One of the best <b>Insider Track</b> strategies involves mimicking the trades of particularly successful insiders. These are investment firms, CEOs and company owners that have an unusual ability to buy the dips.</p><p><b>B. Riley Financial</b>. The boutique investment bank has a strong track record in trading the companies it owns.</p><ul><li><b>Lazydays Holdings</b> (NASDAQ:<b>LAZY</b>). In July, the investment bank bought over 10,000 LAZY shares in the $12 range before the CEO announced “remarkable performance” figures. Shares would jump to $17.50. Recent market wobbles have sent LAZY back to the $12 range – an opportunity B. Riley has used to add another 20,000 shares.</li></ul><p><b>Opaleye LLC</b>. Opaleye LLC has a notable record of picking biotech winners. A $16 million investment in <b>Travere Therapeutics</b> (NASDAQ:<b>TVTX</b>) in 2014 is now worth almost $50 million, and a smaller investment in <b><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a></b> (NASDAQ:<b>OCUL</b>) netted an even more significant 400% return in 2020. Now, the company has added shares in:</p><ul><li><b>TELA Bio</b> (NASDAQ:<b><u>TELA</u></b>). Since June, Opaleye has snapped up shares of TELA in the $5.75 to $8.25 range in seven transactions. The commercial-stage medical tech firm produces products for soft-tissue reconstruction in hernias, plastic and reconstructive surgery. The firm has a stable business, so Opaleye is likely buying as a valuation play.</li><li><b>TRACON Pharmaceuticals</b> (NASDAQ:<b>TCON</b>). The biotech research firm is developing an oncology drug that targets the PD-L1 antibody, a known pathway under study by other large cancer research firms. The drug is now in its pivotal Phase 2 trial, giving the stock a significant upside on any good news.</li><li><b>Protara Therapeutics</b> (NASDAQ:<b>TARA</b>). The New York-based biopharma company has two development programs in its pipeline. OK-432 is designed to treat lymphatic malformations, a common disease thought to affect 1 in every 4,000 live births, and TARA-002, a treatment for bladder cancer. Opaleye’s 19,400 share addition in mid-September brings its stake to 2,575,77, a significant stake in a company with potential blockbusters in its pipeline.</li></ul><h3>Biotech Stocks</h3><p>Opaleye’s investments represent bets on biotech — some of the hardest decisions for the <b>Insider Track</b> strategy. Many of these R&amp;D firms are riding on a single drug candidate, meaning one failed trial will send the stock to zero. And as outsiders, we can’t tell the difference between opportunistic insider buying versus “pump and dumps.”</p><p><i>But biotechs are also some of the most lucrative bets, as Longeveron shows.</i></p><p>That’s because biotech executives often know clinical trial results years before the studies publish official results. If half of your patients suddenly stop developing cancers, you don’t need to be a rocket scientist (or a biotech CEO) to realize your therapy is probably outperforming the placebo in your double-blind study. These executives are also generally aware of how discussions with healthcare regulators are progressing.</p><p>That leads us to three biotech stocks where insiders have recently bought significant stakes.</p><p><b>Zivo Bioscience</b> (NASDAQ:<b>ZIVO</b>). Director Christopher Maggiore joined CEO John Payne in buying shares in the $3.50 range after shares fell from over $5. The company develops algae-based products for food-based ingredients and has a market value of under $30 million. It’s a risky bet, but Mr. Maggiore’s $25,000 share purchase suggests he knows something we don’t.</p><p><b><a href=\"https://laohu8.com/S/BTTX\">Better Therapeutics</a></b> (NASDAQ:<b>BTTX</b>). The prescription digital therapeutics firm has seen a recent rash of cluster buying. The company’s CEO, CFO and a 10% owner have added $304,000 to their stakes since Sept. 12, a telling sign that the firm might have stumbled on a working therapy. Management previously indicated that its most promising candidate, BT-001, could advance pivotal trials this year or early 2023. Trades centered in the $2 range.</p><p><b>TransCode Therapeutics</b> (NASDAQ:<b>RNAZ</b>). The firm’s CEO and 10% owner added 20,000 shares on Sept. 14, raising his stake to 893,114 shares. The firm has a single therapeutic candidate, TTDX-MC138, in its pipeline designed to treat metastatic cancer. The drug is in preclinical trials, meaning that any good news could send shares up several times over.</p><h2>Insider Purchases of Public Offerings</h2><p>Public offerings are one of the best ways to understand insider sentiment. Management can spend months preparing these offerings, giving them a clear idea of the issue’s true value as Elon Musk demonstrated in his 2019 TSLA purchase.</p><p><b>Larimar Therapeutics</b> (NASDAQ:<b>LRMR</b>). The biotech’s CEO, CFO and two directors bought a combined 5.1 million shares at the firm’s public offering price of $3.15. Larimar’s lead candidate CTI-1601 is currently undergoing Phase 1 clinical trials for Friedreich’s ataxia, a rare genetic disease. Shares would jump 15.5% the following day after the FDA lifted a hold on the trial, but such broad insider purchasing often indicates more potential gains.</p><p><b>LinkBancorp</b> (NASDAQ:<b><u>LNKB</u></b>). The Pennsylvania-based bank saw 17 executives and directors buy shares in its recent $7.50 public offer – the same price it offered public investors. One director added 80,000 shares in the $7.70 range after prices jumped in first-day trading. Though outsiders won’t get a clear look into the bank’s recent merger with Gratz until next quarter, insiders seem to believe there’s no need to wait for official pro forma figures to buy at market prices.</p><h2>Cluster Buying</h2><p>Finally, corporate executives often act together in buying company shares. These are some of the most compelling <b>Insider Track</b> investments to make.</p><p><b>Macerich</b> (NYSE:<b>MAC</b>). The Santa Monica-based homebuilder saw six insiders buy 104,617 shares this week, including the company’s CEO, president, CFO, and head of leasing. The company now trades at 0.6x book value, significantly below its historical average of 1.6x.</p><p><b>Liquidia</b> (NASDAQ:<b>LQDA</b>). Shares of the biopharmaceutical company sank 37% in late August after losing a patent battle with <b>United Therapeutics</b> (NASDAQ:<b>UTHR</b>) Insiders, however, have recently bought shares in the $5.50-$6.00 range, including its CEO (45,747 shares), CFO (8000 shares), Commercial SVP (2,160 shares), COO (1,918 shares) and 10% owner <b>Caligan Partners</b> (250,000 shares).</p><p><b><a href=\"https://laohu8.com/S/MFA\">MFA Financial</a></b> (NYSE:<b>MFA</b>). Between Sept. 14-15, the financial firm’s CEO, CFO, Co-CIO and a director added over 10,000 shares to their already-substantial holdings. Shares of MFA have fallen 55% this year over fears about its lending portfolio, particularly from its high exposure to residential whole loans. Insiders are buying shares as if the worries are wildly overblown.</p><p><b>B. Riley Financial</b> (NASDAQ:<b>RILY</b>). The company’s CEO Andrew Moore and director Randall Paulson joined owner Bryant Riley this week in snapping up a combined 48,400 shares in the boutique investment banking and wealth management firm. Shares currently trade at under 6x price-earnings, making it one of the cheapest investment banks by that metric.</p><p><b>Tilly’s</b> (NYSE:<b>TLYS</b>). The CFO of the youth-oriented shoe and clothing retailer joined two directors this week in buying up shares in the $6-$7 range. Tilly’s recent share slide now prices the retailer at 1.5x EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation and amortization), around a quarter of its usual value. Given its high operating leverage, a stronger-than-expected back-to-school season could send shares up 2x-3x from current prices.</p><p><b>L. B. Foster</b> (NASDAQ:<b>FSTR</b>). The CEO and CFO of the railroad infrastructure firm bought another 4,000 shares on Sept. 13, increasing their combined stake to over 110,000. The company trades for under 0.6x price-book, its lowest valuation since February 2016. The last time that happened, shares would recover within two months, earning investors a 60% return within two months and another 30% return within the next 10.</p><h2>Conclusion: How to Use the Insider Track</h2><p>Not all insider purchases are created equal.</p><p>Some industries like biotech, metals and mining are a treasure trove of opportunity. Executives are often aware of promising new drugs and dig sites long before the companies are required by the SEC to disclose material findings.</p><p>Following executives in other sectors comes with greater risks. Are insiders at <b>Exxon</b> (NYSE:<b>XOM</b>) buying because of an unannounced deal? Or are they blindly speculating on oil prices instead?</p><p>That’s why I tend to avoid companies like <b>HighPeak Energy</b> (NASDAQ:<b>HPK</b>), <b>U.S. Energy Corp</b> (NASDAQ:<b>USEG</b>) and <b>Stronghold Digital Mining</b> (NASDAQ:<b>SDIG</b>) — firms that also recently announced insider purchases. Shares in these firms more closely track the price of oil and <b>Bitcoin</b> (<b><u>BTC-USD</u></b>) – assets that no executive can predict.</p><p>Instead, I focus on bets with particularly opaque financials and high operating leverage. And though every investment requires deeper research before jumping in, the <b>Insider Track</b> provides us with a strong starting point to beating the markets.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsider Buying 2022: 15 Stocks to Bet On Despite the Bear Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-07 10:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech firm working on a promising Alzheimer’s therapy.Within six weeks, shares had risen over 11x… a ...</p>\n\n<a href=\"https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4094":"服装零售","PSQ":"纳指反向ETF","MFA":"MFA Financial","BTTX":"Better Therapeutics","BK4110":"抵押房地产投资信托","TLYS":"Tilly’s","BK4099":"汽车制造商","BK4511":"特斯拉概念","BK4183":"个人用品","XOM":"埃克森美孚","BK4127":"投资银行业与经纪业","TQQQ":"纳指三倍做多ETF","USEG":"美国能源","MAC":"马塞里奇房产","BK4213":"石油与天然气的勘探与生产","RILY":"B. Riley Financial, Inc.",".IXIC":"NASDAQ Composite","BK4539":"次新股","QLD":"纳指两倍做多ETF","BK4516":"特朗普概念","BK4023":"应用软件","LQDA":"Liquidia Technologies Inc","ZIVO":"Zivo Bioscience, Inc.","TELA":"TELA Bio, Inc.","QQQ":"纳指100ETF","BK4532":"文艺复兴科技持仓","BK4570":"地缘局势概念股","SQQQ":"纳指三倍做空ETF","BK4214":"汽车零售","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4139":"生物科技","TVTX":"Travere Therapeutics, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","RNAZ":"TransCode Therapeutics  Inc.","OCUL":"Ocular Therapeutix","BK4080":"零售业房地产投资信托","SDIG":"Stronghold Digital Mining, Inc","FSTR":"LB福斯特","BK4167":"医疗保健技术","BK4527":"明星科技股","LRMR":"Larimar Therapeutics, Inc.","HPK":"Highpeak Energy Acquisition Corp","TARA":"ArTara Therapeutics, Inc.","BK4551":"寇图资本持仓","BK4198":"医疗保健用品","TSLA":"特斯拉","BK4574":"无人驾驶"},"source_url":"https://investorplace.com/2022/10/insider-buying-2022-15-stocks-to-bet-on-despite-the-bear-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2273828361","content_text":"Source: ShutterstockIn October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech firm working on a promising Alzheimer’s therapy.Within six weeks, shares had risen over 11x… a stunning 1,000% return!My secret?I noticed that the biotech’s CFO was quietly buying shares in the company.“With clinical results due within the next month, Longeveron’s executives are likely using their knowledge of the Aging Frailty study to predict a strong outcome in the Alzheimer’s trial.”Just a month later, the company would announce some unexpectedly good news: The U.S. Food and Drug Administration (FDA) approved Longeveron’s Lomecel-B for use!The Secret to Finding 1,000% WinnersIt turns out that Longeveron’s management aren’t the only ones who are suspiciously good at timing their company’s stock.A study by MIT researchers found that insider transactions in the U.S. would have turned $10,000 into $156,000 over their study period, compared to around $50,300 in the S&P 500.That’s because insiders often act on privileged information, both knowingly and unknowingly. If sales figures are doing well… or patients are responding well to clinical trials… they don’t need the “official” SEC filings to decide to buy.Some call it a total scam.And I get it. SEC rules around insider transactions are surprisingly lax; if a CEO sees a new product performing well or is on the cusp of making a massive deal, it’s often entirely legal to trade on that information. In 2018, Tesla (NASDAQ:TSLA) CEO Elon Musk bought $25 million of his company’s shares while details of a massive $2 billion capital raise were still under wraps.TSLA shares would rise 206% within a year.But as I’ve long said, if you can’t beat ’em, you might as well join. If the world’s richest man generated an extra $75 million along the way by using privileged information, isn’t it fair to follow his steps?It’s a strategy I’ve called the Insider Track.The Best Time to Buy… Is in a Bear MarketThe Insider Track strategy has provenly strong results. Since January 2009, C-Suite buying has generated an annualized return of 20.8%, according to tracking site TipRanks. And in the past week alone, insiders have snapped up $45 million of their corporate shares.These amounts are admittedly smaller than in previous declines. In May 2020, insiders bought a stunning $161 million of shares after the Covid-19 slump. And today, many sectors are doing worse than in 2020 because of higher inflation and rising rates.But some American businesses are still humming along. Here are 15 stocks where insiders act as if they know something the market doesn’t.Top Market TimersOne of the best Insider Track strategies involves mimicking the trades of particularly successful insiders. These are investment firms, CEOs and company owners that have an unusual ability to buy the dips.B. Riley Financial. The boutique investment bank has a strong track record in trading the companies it owns.Lazydays Holdings (NASDAQ:LAZY). In July, the investment bank bought over 10,000 LAZY shares in the $12 range before the CEO announced “remarkable performance” figures. Shares would jump to $17.50. Recent market wobbles have sent LAZY back to the $12 range – an opportunity B. Riley has used to add another 20,000 shares.Opaleye LLC. Opaleye LLC has a notable record of picking biotech winners. A $16 million investment in Travere Therapeutics (NASDAQ:TVTX) in 2014 is now worth almost $50 million, and a smaller investment in Ocular Therapeutix (NASDAQ:OCUL) netted an even more significant 400% return in 2020. Now, the company has added shares in:TELA Bio (NASDAQ:TELA). Since June, Opaleye has snapped up shares of TELA in the $5.75 to $8.25 range in seven transactions. The commercial-stage medical tech firm produces products for soft-tissue reconstruction in hernias, plastic and reconstructive surgery. The firm has a stable business, so Opaleye is likely buying as a valuation play.TRACON Pharmaceuticals (NASDAQ:TCON). The biotech research firm is developing an oncology drug that targets the PD-L1 antibody, a known pathway under study by other large cancer research firms. The drug is now in its pivotal Phase 2 trial, giving the stock a significant upside on any good news.Protara Therapeutics (NASDAQ:TARA). The New York-based biopharma company has two development programs in its pipeline. OK-432 is designed to treat lymphatic malformations, a common disease thought to affect 1 in every 4,000 live births, and TARA-002, a treatment for bladder cancer. Opaleye’s 19,400 share addition in mid-September brings its stake to 2,575,77, a significant stake in a company with potential blockbusters in its pipeline.Biotech StocksOpaleye’s investments represent bets on biotech — some of the hardest decisions for the Insider Track strategy. Many of these R&D firms are riding on a single drug candidate, meaning one failed trial will send the stock to zero. And as outsiders, we can’t tell the difference between opportunistic insider buying versus “pump and dumps.”But biotechs are also some of the most lucrative bets, as Longeveron shows.That’s because biotech executives often know clinical trial results years before the studies publish official results. If half of your patients suddenly stop developing cancers, you don’t need to be a rocket scientist (or a biotech CEO) to realize your therapy is probably outperforming the placebo in your double-blind study. These executives are also generally aware of how discussions with healthcare regulators are progressing.That leads us to three biotech stocks where insiders have recently bought significant stakes.Zivo Bioscience (NASDAQ:ZIVO). Director Christopher Maggiore joined CEO John Payne in buying shares in the $3.50 range after shares fell from over $5. The company develops algae-based products for food-based ingredients and has a market value of under $30 million. It’s a risky bet, but Mr. Maggiore’s $25,000 share purchase suggests he knows something we don’t.Better Therapeutics (NASDAQ:BTTX). The prescription digital therapeutics firm has seen a recent rash of cluster buying. The company’s CEO, CFO and a 10% owner have added $304,000 to their stakes since Sept. 12, a telling sign that the firm might have stumbled on a working therapy. Management previously indicated that its most promising candidate, BT-001, could advance pivotal trials this year or early 2023. Trades centered in the $2 range.TransCode Therapeutics (NASDAQ:RNAZ). The firm’s CEO and 10% owner added 20,000 shares on Sept. 14, raising his stake to 893,114 shares. The firm has a single therapeutic candidate, TTDX-MC138, in its pipeline designed to treat metastatic cancer. The drug is in preclinical trials, meaning that any good news could send shares up several times over.Insider Purchases of Public OfferingsPublic offerings are one of the best ways to understand insider sentiment. Management can spend months preparing these offerings, giving them a clear idea of the issue’s true value as Elon Musk demonstrated in his 2019 TSLA purchase.Larimar Therapeutics (NASDAQ:LRMR). The biotech’s CEO, CFO and two directors bought a combined 5.1 million shares at the firm’s public offering price of $3.15. Larimar’s lead candidate CTI-1601 is currently undergoing Phase 1 clinical trials for Friedreich’s ataxia, a rare genetic disease. Shares would jump 15.5% the following day after the FDA lifted a hold on the trial, but such broad insider purchasing often indicates more potential gains.LinkBancorp (NASDAQ:LNKB). The Pennsylvania-based bank saw 17 executives and directors buy shares in its recent $7.50 public offer – the same price it offered public investors. One director added 80,000 shares in the $7.70 range after prices jumped in first-day trading. Though outsiders won’t get a clear look into the bank’s recent merger with Gratz until next quarter, insiders seem to believe there’s no need to wait for official pro forma figures to buy at market prices.Cluster BuyingFinally, corporate executives often act together in buying company shares. These are some of the most compelling Insider Track investments to make.Macerich (NYSE:MAC). The Santa Monica-based homebuilder saw six insiders buy 104,617 shares this week, including the company’s CEO, president, CFO, and head of leasing. The company now trades at 0.6x book value, significantly below its historical average of 1.6x.Liquidia (NASDAQ:LQDA). Shares of the biopharmaceutical company sank 37% in late August after losing a patent battle with United Therapeutics (NASDAQ:UTHR) Insiders, however, have recently bought shares in the $5.50-$6.00 range, including its CEO (45,747 shares), CFO (8000 shares), Commercial SVP (2,160 shares), COO (1,918 shares) and 10% owner Caligan Partners (250,000 shares).MFA Financial (NYSE:MFA). Between Sept. 14-15, the financial firm’s CEO, CFO, Co-CIO and a director added over 10,000 shares to their already-substantial holdings. Shares of MFA have fallen 55% this year over fears about its lending portfolio, particularly from its high exposure to residential whole loans. Insiders are buying shares as if the worries are wildly overblown.B. Riley Financial (NASDAQ:RILY). The company’s CEO Andrew Moore and director Randall Paulson joined owner Bryant Riley this week in snapping up a combined 48,400 shares in the boutique investment banking and wealth management firm. Shares currently trade at under 6x price-earnings, making it one of the cheapest investment banks by that metric.Tilly’s (NYSE:TLYS). The CFO of the youth-oriented shoe and clothing retailer joined two directors this week in buying up shares in the $6-$7 range. Tilly’s recent share slide now prices the retailer at 1.5x EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation and amortization), around a quarter of its usual value. Given its high operating leverage, a stronger-than-expected back-to-school season could send shares up 2x-3x from current prices.L. B. Foster (NASDAQ:FSTR). The CEO and CFO of the railroad infrastructure firm bought another 4,000 shares on Sept. 13, increasing their combined stake to over 110,000. The company trades for under 0.6x price-book, its lowest valuation since February 2016. The last time that happened, shares would recover within two months, earning investors a 60% return within two months and another 30% return within the next 10.Conclusion: How to Use the Insider TrackNot all insider purchases are created equal.Some industries like biotech, metals and mining are a treasure trove of opportunity. Executives are often aware of promising new drugs and dig sites long before the companies are required by the SEC to disclose material findings.Following executives in other sectors comes with greater risks. Are insiders at Exxon (NYSE:XOM) buying because of an unannounced deal? Or are they blindly speculating on oil prices instead?That’s why I tend to avoid companies like HighPeak Energy (NASDAQ:HPK), U.S. Energy Corp (NASDAQ:USEG) and Stronghold Digital Mining (NASDAQ:SDIG) — firms that also recently announced insider purchases. Shares in these firms more closely track the price of oil and Bitcoin (BTC-USD) – assets that no executive can predict.Instead, I focus on bets with particularly opaque financials and high operating leverage. And though every investment requires deeper research before jumping in, the Insider Track provides us with a strong starting point to beating the markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9913293121,"gmtCreate":1663987136363,"gmtModify":1676537375807,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a>zzz omg","listText":"<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a>zzz omg","text":"$Amazon.com(AMZN)$zzz omg","images":[{"img":"https://community-static.tradeup.com/news/c2b49f8587361c2be013576dc4ac75f0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9913293121","isVote":1,"tweetType":1,"viewCount":34,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9913306379,"gmtCreate":1663903698091,"gmtModify":1676537360694,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>zzz","listText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>zzz","text":"$AMC Entertainment(AMC)$zzz","images":[{"img":"https://community-static.tradeup.com/news/df143f0c2be01ee379d6b05dddc71867","width":"1080","height":"2287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9913306379","isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9902044634,"gmtCreate":1659620306531,"gmtModify":1705987876882,"author":{"id":"4115099382320642","authorId":"4115099382320642","name":"AhBeee","avatar":"https://community-static.tradeup.com/news/cc39d8922b481acc8b9f92f27eb989b9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>can buy?","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>can buy?","text":"$Palantir Technologies Inc.(PLTR)$can buy?","images":[{"img":"https://community-static.tradeup.com/news/ed2c54d3b345293bfcf038f3cb614736","width":"1080","height":"3195"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902044634","isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}